Curriculum Vitae

Personal information

Melissa van Tok

Work experience

Work experience

Current:

Start date: September 2023

Position: Clinical Assessor

Employer: CBG_MEB

Country: Netherlands

Past:

Start date: June 2019

End date: August 2023

Position: Medical Science Liaison/Medical Advisor

Employer: Merck BV

Country: Netherlands

Start date: November 2014

End date: January 2019

Position: PhD student

Employer: Academic Medical Center/University of Amsterdam

Country: Netherlands

Start date: July 2011

End date: November 2014

Position: laboratory technician

Employer: Academic Medical Center/University of Amsterdam

Country: Netherlands

Education and training

Education and training

Start date: November 2014

End date: January 2019

Qualification: PhD

Institution: University of Amsterdam

Country: Netherlands

Subject: Thesis: preclinical studies of spondyloarthritis. Development of two novel disease models and pharmacologic targeting of the IL-17 pathway.

Start date: November 2014

End date: January 2017

Qualification: Immunology

Institution: various universities

Country: Netherlands

Subjects: additional courses on immunology

Start date: September 2007

End date: July 2011

Degree: BsC medical biology

Institution: Hogeschool Utrecht, institute for life science and chemistry

Country: Netherlands

Additional information

Publications

Main publications:

Van Tok MN, Mandour M, Wahle J, Labadia ME, van de Sande MGH, Nabozny G, Baeten DL, van Duivenvoorde LM, paradoxical augmentation of experimental spondyloarthritis by RORC inhibition in HLA-B27 transgenic rats Front Immunol. 2021

Kaaij MH, van Tok MN, Blijdorp IC, Ambarus CA, Stock M, Pots D, Knaup VL, Armaka M, Christodoulou-Vafeiadou E, Melsen TK, Masdar H, Eskes HJPP, Yeremenko NG, Kollias G, Schett G, Tas SW, van Duivenvoorde LM, Baeten DLP. Transmembrane TNF drives osteoproliferative joint inflammation reminiscent of human spondyloarthritis. J Exp Med 2020

Chen S, van Tok MN, Knaup VL, Kraal L, Pots D, Bartels L, Gravallese EM, Taurog JD, van de Sande M, van Duivenvoorde LM, Baeten DL. mTOR blockade by rapamycin in spondyloarthritis: impact on inflammation and new bone formation in vitro and in vivo. Front Immunol 2020

Van Tok MN, van Duivenvoorde LM, Kramer I, Ingold P, Pfister S, Blijdorp I.C., Taurog JD, Kolbinger F, Baeten DL. Blockade of IL-17A diminishes Inflammation And New Bone Formation In Spondyloarthritis. Arthritis Rheumatol 2018

Van Tok MN, Na S, Pots D., Taurog JD, Baeten DL, van Duivenvoorde LM. The Initiation, But Not The Persistence, Of Experimental Spondyloarthritis is Crucially Dependent On The IL-23 Axis. Front Immunol 2018

Van Duivenvoorde LM, van Tok MN, Knaup VL, Blijdorp IC, Ambarus CA, Armaka M, van Melsen TK, Masdar H, Eskes HJPP, Kollias G, Yeremenko NG, Baeten DL. The transmembrane form of tumor necrosis factor drives osteoproliferative joint inflammation reminiscent of human spondyloarthritis. In revision.

Van Tok MN, Satumtira N, Dorris M, Pots D, Slobodin G, Taurog JD, Baeten DL, van Duivenvoorde LM. Innate Immune Activation Triggers Experimental Spondyloarthritisin HLA B27/Hub2m Transgenic Rats. Front. Immunol. 2017

Van Tok MN, Yeremenko NG, Teitsma CA, Kream BE, Knaup VL, Lories RJ, Baeten DL, van Duivenvoorde LM. Insulin-Like Growth Factor I does not drive new bone formation in experimental arthritis. PloS One 2016

Projects

Memberships

Other Relevant Information